Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$1.1 million.

  • BioNexus Gene Lab's Change in Account Payables fell 65580.23% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$765280.0, marking a year-over-year decrease of 17878.24%. This contributed to the annual value of $204342.0 for FY2024, which is 15359.19% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Change in Account Payables stood at -$1.1 million for Q3 2025, which was down 65580.23% from $204963.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Change in Account Payables' 5-year high stood at $649741.0 during Q4 2022, with a 5-year trough of -$1.1 million in Q3 2025.
  • Moreover, its 5-year median value for Change in Account Payables was -$208629.0 (2022), whereas its average is -$142349.2.
  • In the last 5 years, BioNexus Gene Lab's Change in Account Payables soared by 287149.2% in 2024 and then tumbled by 67493.98% in 2025.
  • BioNexus Gene Lab's Change in Account Payables (Quarter) stood at -$393084.0 in 2021, then soared by 265.29% to $649741.0 in 2022, then crashed by 102.57% to -$16676.0 in 2023, then skyrocketed by 2871.49% to $462174.0 in 2024, then crashed by 341.23% to -$1.1 million in 2025.
  • Its Change in Account Payables stands at -$1.1 million for Q3 2025, versus $204963.0 for Q2 2025 and -$317522.0 for Q1 2025.